The Indian Pharmacopoeia Commission held a two-day National Conference on the quality and safety of biosimilars on 10-11 September 2026 at C-CAMP, Bengaluru, with 160 participants from regulators, industry, academia and research bodies.
Its main output was the release of an Indian Pharmacopoeia Reference Substance for enoxaparin sodium for bioassays, an authenticated reference material for testing the drug's biological activity.
The conference was framed around the government's Biopharma SHAKTI vision and organised with IDMA, with BIRAC and C-CAMP as knowledge partners and KDPMA as associate partner.
GS Paper 2 > Governance > Health; GS Paper 3 > Science and Technology > Biotechnology
A biological medicine shown to be similar in quality, safety and efficacy to an already approved reference biologic; unlike a chemical generic it can never be an identical copy, which is why comparability and immunogenicity testing are required.
An authenticated material of known quality issued by the pharmacopoeial authority, against which laboratories calibrate tests of a drug's identity, purity or biological activity.